Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

618

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: Cabotegravir (CAB) tablet
DRUG: Rilpivirine (RPV) tablet
DRUG: Cabotegravir - Injectable Suspension (CAB LA)
DRUG: Rilpivirine - Injectable Suspension (RPV LA)
DRUG: 2 NRTIs plus an INI, NNRTI, or PI

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]